Market Cap | 7.43M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -20.62M | Forward P/E | -1.78 | EPS next Y | - | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -28.00% |
Dividend | N/A | Price/Book | 0.32 | EPS next 5Y | - | 52W High Chg | -82.00% |
Recommedations | 2.00 | Quick Ratio | 0.51 | Shares Outstanding | 1.39M | 52W Low Chg | 46.00% |
Insider Own | 16.72% | ROA | -72.70% | Shares Float | 1.18M | Beta | 1.85 |
Inst Own | 10.71% | ROE | -232.97% | Shares Shorted/Prior | 15.99K/12.32K | Price | 0.29 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 287,517 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 15 | Volume | 44,599 | Change | -3.98% |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Roemer Alan S. | Director Director | Nov 21 | Sell | 2.05 | 7,825 | 16,041 | 11/22/23 | |
Verstandig Grant | Director Director | Jun 03 | Buy | 2.22 | 66,876 | 148,465 | 1,053,619 | 06/07/22 |
Verstandig Grant | Director Director | May 31 | Buy | 2.24 | 133,124 | 298,198 | 950,519 | 06/02/22 |
BARER SOL J | Director Director | May 31 | Buy | 2.26 | 100,000 | 226,000 | 1,557,094 | 06/02/22 |
Jones Kristi | President and CEO President and CEO | Mar 29 | Buy | 3.74 | 10,000 | 37,400 | 73,078 | 03/30/22 |
BARER SOL J | Director Director | Mar 23 | Buy | 2.6653 | 10,000 | 26,653 | 1,517,814 | 03/24/22 |